<DOC>
	<DOCNO>NCT01378676</DOCNO>
	<brief_summary>The study generate data safety tolerability multiple daily dos CK-2017357 patient ALS . Patients randomize one four different treatment group , receive daily oral dos either placebo , 125 mg , 250 mg , 375 mg CK-2017357 14 day .</brief_summary>
	<brief_title>A Study Evaluate Effects Multiple Doses CK-2017357 Patients With Amyotrophic Lateral Sclerosis ( ALS )</brief_title>
	<detailed_description>In Part A , approximately 24 patient randomize one four different treatment group . After 7-day washout riluzole , patient treatment group receive daily oral dos placebo , 125 mg , 250 mg , 375 mg CK-2017357 14 day . Patients take daily dos CK-2017357 placebo ( Day 1 Day 14 ) return study site Day 2 , Day 8 Day 15 . All patient return follow-up visit 7 day ( Â± 2 day ) last dose . In Part B , approximately 24 patient randomize one four different treatment group Part A . Patients Part B require decrease riluzole dose 50 mg day ( QD ) 7 day prior randomization . After 7 day period , patient take riluzole 50 mg QD concurrently morning dose blind study drug .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>Key 1 . Able comprehend willing sign Informed Consent Form ( ICF ) 2 . Males females 18 year age old 3 . A diagnosis familial sporadic ALS ( define meeting possible , laboratorysupported probable , probable , definite criterion diagnosis ALS accord World Federation Neurology El Escorial criterion ) 4 . Maximum voluntary grip strength least one hand 10 &amp; 40 pound ( female ) 10 &amp; 60 pound ( male ) 5 . Upright Slow Vital Capacity ( SVC ) &gt; 50 % predicted age , height , sex 6 . Able swallow tablet water 7 . Willing able remain riluzole 4 week ( Part A ) 8 . Currently take tolerate stable dose 50 mg BID riluzole ( Part B ) 9 . Willing able reduce daily dose riluzole 50 mg 4 week ( Part B ) 10 . Willing able refrain caffeinecontaining product study participation 11 . Willing able remain warfarin theophyllinecontaining medication study participation 12 . Has caregiver capable observe report patient status , also assist proper use nocturnal oximetry equipment 13 . Able perform pulmonary function test Key 1 . Life expectancy &lt; 3 month 2 . Participation trial receipt investigational study drug occur within 30 day 5 halflives prior agent , whichever great , prior dose 3 . Any prior treatment CK2017357 4 . Use noninvasive positive pressure ventilation ( NIPPV ) part day night Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>